Literature DB >> 25460106

The use of methylamphetamine chemical profiling in an intelligence-led perspective and the observation of inhomogeneity within seizures.

Marie Morelato1, Alison Beavis1, Mark Tahtouh2, Olivier Ribaux3, K Paul Kirkbride4, Claude Roux5.   

Abstract

This study focuses on methylamphetamine (MA) seizures made by the Australian Federal Police (AFP) to investigate the use of chemical profiling in an intelligence perspective. Correlation coefficients were used to obtain a similarity degree between a population of linked samples and a population of unlinked samples. Although it was demonstrated that a general framework can be followed for the use of any forensic case data in an intelligence-led perspective, threshold values have to be re-evaluated for each type of illicit drug investigated. Unlike the results obtained in a previous study on 3,4-methylenedioxymethylamphetamine (MDMA) seizures, chemical profiles of MA samples coming from the same seizure showed relative inhomogeneity, limiting their ability to link seizures. Different hypotheses were investigated to obtain a better understanding of this inhomogeneity although no trend was observed. These findings raise an interesting discussion in regards to the homogeneity and representativeness of illicit drug seizures (for intelligence purposes). Further, it also provides some grounds to discuss the initial hypotheses and assumptions that most forensic science studies are based on.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Forensic intelligence; Illicit drug profiling; Methylamphetamine; Representativeness; Seizure homogeneity

Mesh:

Substances:

Year:  2014        PMID: 25460106     DOI: 10.1016/j.forsciint.2014.10.041

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  1 in total

1.  Profiling of cocaine using ratios of GC-MS peaks.

Authors:  Palle Villesen; Louise Stride Nielsen
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.